trial · primary record
Experimental: YB-101
Graves' Disease
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 232 |
| Primary completion | 2029-09 |
| Primary endpoint | Type and frequency of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs) |
| Registry ID | NCT07682896 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:14.513Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07682896
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.